Arterys Cardio DL vs Tempus ECG-Low EF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Arterys (now part of Tempus)
VS
by Tempus

AI Verdict

Arterys Cardio DL is designed for advanced analysis of cardiac MRI scans, offering automated segmentations and detailed quantification to improve diagnostic accuracy and efficiency in radiology workflows. In contrast, Tempus ECG-Low EF focuses on screening 12-lead ECGs to detect signs associated with low left ventricular ejection fraction, serving as an early identification tool for patients at risk of heart failure. While both leverage AI in cardiology, they operate on different diagnostic modalities and serve distinct purposes in the patient care pathway.

Choose Arterys Cardio DL if…

Choose Arterys Cardio DL if your primary need is advanced, efficient, and highly accurate analysis of cardiac MRI studies. This cloud-based AI solution is ideal for cardiologists and radiologists requiring automated ventricle segmentations, 4D Flow post-processing, and quantitative delayed enhancement to drastically reduce interpretation time and enhance diagnostic precision for complex cardiac imaging.

View Arterys Cardio DL →

Choose Tempus ECG-Low EF if…

Choose Tempus ECG-Low EF if you need a rapid, AI-powered screening tool to identify patients at risk of low left ventricular ejection fraction (LVEF ≤40%) using standard 12-lead ECGs. This software is best suited for clinical settings like emergency medicine, internal medicine, or cardiology clinics where early detection and risk stratification for heart failure are crucial for patients 40 years or older.

View Tempus ECG-Low EF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Arterys Cardio DL Tempus ECG-Low EF
Deployment Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27] Integrates with current ECG platforms and electronic health records (EHRs).
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Arterys Cardio DL

Arterys Cardio DL is cloud-based, offering rapid analysis (seconds vs. 30-60 minutes) and editable automated contours, which significantly streamlines workflow and enhances efficiency for complex cardiac MRI interpretations. Its vendor-agnostic compatibility and cloud deployment also suggest easier access and integration compared to software requiring integration into existing facility workflows.

Clinical Value

Tempus ECG-Low EF

Tempus ECG-Low EF leverages a widely available and inexpensive test (ECG) to identify patients at risk of low LVEF, a critical indicator for heart failure, potentially enabling earlier intervention for a broad patient population. While Arterys Cardio DL provides detailed MRI analysis, Tempus's ability to offer early risk stratification from a common test has a significant and widespread clinical impact.

Pricing & Value

Tie

Both tools require contacting the vendor for pricing, which limits transparency and makes a direct cost comparison impossible. While both offer substantial clinical value in their respective domains, without specific pricing details, it's not possible to determine which provides better value for money.

Enterprise Readiness

Arterys Cardio DL

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating strong foundational enterprise readiness. However, Arterys Cardio DL's cloud-based deployment and explicit 'vendor-agnostic compatibility' suggest greater flexibility and potentially simpler integration across diverse enterprise IT environments.

Innovation

Arterys Cardio DL

Arterys Cardio DL is described as 'the world's first internet platform for medical imaging' and the 'first technology to be cleared by the FDA that leverages cloud computing and deep learning in a clinical setting,' indicating a foundational innovation in medical imaging architecture. Its advanced features like 4D Flow and Quantitative Delayed Enhancement further highlight its innovative capabilities in complex MRI analysis.

Support & Docs

Tie

The provided structured facts and web searches do not offer sufficient comparative detail on the quality, availability, or types of support and documentation for either tool. As both are FDA-cleared medical software, robust support and documentation are expected, but a definitive winner cannot be determined without more specific information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Arterys Cardio DL Tempus ECG-Low EF
Name Arterys Cardio DL Tempus ECG-Low EF
Company ARTERYS Tempus AI
Description FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy. FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation.
Primary Function Automated, editable ventricle segmentations for cardiac MRI analysis Analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%)
Target Patient Population/Data Cardiac MRI Patients 40 years or older at risk of heart failure, using 12-lead ECG recordings

Videos

Demos, reviews, and walkthroughs featuring Arterys Cardio DL and Tempus ECG-Low EF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Arterys Cardio DL is designed to analyze cardiac MRI images, providing automated ventricle segmentations and advanced post-processing features. Tempus ECG-Low EF, on the other hand, analyzes resting, non-ambulatory 12-lead ECG recordings to detect specific cardiac signs.
Arterys Cardio DL aims to drastically reduce cardiac MRI interpretation time and enhance diagnostic accuracy through automated segmentations and quantitative analysis. Tempus ECG-Low EF is intended to aid clinicians in identifying patients 40 years or older at risk of heart failure by detecting signs associated with low left ventricular ejection fraction (LVEF u226440%) from ECGs.
Arterys Cardio DL provides editable, automated ventricle segmentations, 4D Flow visualization, and quantitative Delayed Enhancement analysis for detailed cardiac MRI assessment. Tempus ECG-Low EF provides a binary output (Low LVEF Detected / Not Detected) to indicate the presence of signs associated with low LVEF, prompting further evaluation.
Arterys Cardio DL is primarily intended for Cardiology and Radiology specialists due to its focus on cardiac MRI analysis. Tempus ECG-Low EF is relevant for Cardiology, Emergency Medicine, and Internal Medicine, as it aids in identifying at-risk patients from ECGs.
No, they serve different patient populations and use cases. Arterys Cardio DL is for general cardiac MRI analysis across various cardiac conditions. Tempus ECG-Low EF is specifically for patients 40 years or older at risk of heart failure, detecting low LVEF from resting 12-lead ECGs.

Backers

Who funded each tool's parent company.

Tempus ECG-Low EF

AI Tool Finder
AI-powered search. Results may not be comprehensive.